Wilms Tumor 1 (WT1) antibody

Antigen: Wilms Tumor 1 (WT1)

Synonyms: GUD, WAGR, WT33, WIT-2, WT1, WT, wt1-A, xWT1, CWT1, WT-1, wt1, MGC152697, zgc:152697, si:ch211-160j6.3, gud, wagr, wt-1, wt33, xwt1, wit-2

Clonality: Monoclonal (6F-H2)

Host: Mouse

Reactivity: Human

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Catalog no.: ABIN125232

Additional Information

Alternative name: Wilms Tumor 1 Protein (WT1)

Immunogen: BALB/C mice were injected with truncated human WT1 protein corresponding to N-terminal amino acids 1-181.

Isotype: IgG1  (Matching secondary antibodies)

Clone: 6F-H2

Specificity: Wilms' Tumor (WT1), is a gene involved in the induction of Wilms

Application Details

Application Notes: Titer/Working Dilution: This antibody may be diluted to a titer of 1:15-1:25 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 to 60 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM Citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Wilms

Concentration: 100ug/ml approximately

Buffer: This antibody is supplied as tissue culture supernatant containing BSA and sodium azide as preservative.

Storage: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Restrictions: For Research Use. CE-certified for In Vitro Diagnostics (IVD) Use in the European Union

Publications

Publications: Haber, Buckler: "WT1: a novel tumor suppressor gene inactivated in Wilms' tumor." in: The New biologist, Vol. 4, Issue 2, pp. 97-106, 1992 (PubMed).

Menssen, Renkl, Rodeck et al.: "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 9, Issue 6, pp. 1060-7, 1995 (PubMed).

Kumar-Singh, Segers, Rodeck et al.: "WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis." in: The Journal of pathology, Vol. 181, Issue 1, pp. 67-74, 1997 (PubMed).